|
By clicking to begin a simulation, you are acknowledging that you have reviewed the CME information below.
Cases Developed by Expert Faculty
Peter C. Enzinger, MD
Clinical Director and Staff Physician
Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Axel F. Grothey, MD
Professor of Oncology and Consultant
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Independent Reviewer
Alexandre Hageboutros, MD
Associate Division Head
Director, Fellowship Program
Associate Professor of Medicine
Cooper Cancer Institute
Camden, New Jersey
Release Date
March 16, 2009 (valid until March 15, 2010)
Introduction
Colorectal cancer (CRC) ranks third in the United States among cancers of both men and women with over 150,000 cases diagnosed annually. While it represents the second leading cause of cancer-related death, there is new reason for hope as the death rate has been declining for the past 15 years.
Recent progress in patient outcomes with colorectal cancer reflects the introduction of novel drugs and innovative strategies, including adjuvant therapy for localized, high-risk cancers and multimodal stance for advanced or metastatic disease. Amidst such rapid advances, however, the complexities of treatment have precipitously escalated.
The goal of this activity is to provide the learner with the latest data and expert peer insights to improve the competence of activity participants involved in the management patients with colorectal cancer.
Target Audience
This activity is specifically designed for medical oncologists who manage patients with colorectal cancer. Other healthcare professionals interested in this topic may also participate.
Learning Objectives
Upon completing this educational activity, participants should be able to:
- Describe the use and efficacy of currently available biologic agents for treatment of colorectal cancer.
- List major side effects or other limitations of combination therapy that may impact timing or duration of colorectal cancer treatment.
- Describe therapeutic sequencing for colorectal cancer, based on existing clinical studies and expert consensus.
- Implement into clinical practice potential strategies for maintenance therapy, either continuous or intermittent, during the course of advanced colorectal cancer treatment.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of CME and CASIVUS Specialty Communications. The American Academy of CME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Academy designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Receiving Credit
The estimated time for the completion of this activity—which consists of three (3) cases—is 1.5 hours. To be eligible for CME credit, participants must complete one or more cases and complete the activity evaluation. Upon submission of the evaluation, you will immediately receive your certificate, which you may print and/or save as documentation of completion. You can only claim and receive credit for this activity once. If you plan to complete more than one case today, or if you plan to return at a later date to complete and claim credit for additional cases, please wait to claim your credit until you have completed all the cases which you intend to complete.
Commercial Supporters
This activity is supported by an educational grant from Bristol-Myers Squibb and ImClone Systems, Inc.
Disclosures
Faculty
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Peter Enzinger, MD, discloses that he is a member of the advisory boards for scientific information for Imclone and sanofi-aventis. He is a member of the promotional speaker’s bureaus for Imclone, Roche, and sanofi-aventis.
Axel Grothey, MD, discloses that he is a member of the Advisory Board for scientific information for Amgen, Bayer, Bristol-Myers Squibb, Genentech, Pfizer, Roche, and Sanofi-Aventis. He is a consultant for clinical trial design for Amgen, Bayer, Genentech, and Pfizer.
Alexandre Hageboutros, MD, independent reviewer, discloses that he is a member of the promotional speakers’ bureaus (no colorectal cancer-related speaking in the past 12 months) for Genentech and sanofi-aventis.
John JD Juchniewicz, MCIS, American Academy of CME, discloses he was a shareholder in Johnson & Johnson through February 2008.
Dorothy J. Schirf, MD, medical writer, discloses she is a shareholder in Alkermes, Ligand, Northfield Labs, and Pfizer.
Marc Ussini, CASIVUS Specialty Communications, discloses he was an employee of Genentech until August 2008. He is currently a shareholder in Bayer AG, Genentech, Johnson & Johnson, Monsanto, and Pfizer Inc.
Off-Label Disclosure
The faculty has disclosed that this activity includes discussion of either non-FDA-approved or investigational uses of the following agents/devices: panitumumab and cetuximab.
Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Bristol-Myers Squibb, ImClone Systems, Inc., or any other pharmaceutical company, American Academy of CME or CASIVUS Specialty Communications. The recommendations made in this activity are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating faculty. The information provided during this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. Before utilizing any diagnostic procedures or prescribing any medication, participants should appraise the information presented critically and are encouraged to consult primary references and full prescribing information for any test, product or device mentioned in this activity. Please refer to official prescribing information for each product for approved indications, contraindications, and warnings.
Instructions for Participation and Credit
Our Commitment to Privacy
The American Academy of CME, CASIVUS Specialty Communications, and Therasim respects the privacy of every individual who participates in this activity. Because your privacy is important to us, we provide you with notice about the collection and use of your information. By continuing with this activity, you accept the practices described in this privacy notice.
We collect two types of information:
Standard Web server traffic pattern information. General traffic, site usage, and length of stay information is collected and stored in log files. This type of information may be shared externally only on an aggregated basis. We do not use cookies on our Web site.
Personal information. We do not collect personally identifiable information from you unless you provide it to us voluntarily and knowingly. The information you provide in order to provide you with credit for completing the online activity includes the following information: first and last name, street address, city, state, zip code, telephone number, area of practice, email address and other pertinent information. This information will be collected when you claim credit registration form.
We limit the use of information provided to us on the CME site to the following:
We will only use aggregate information derived, in part, from your use of our site to improve our site and our service to you.
We will maintain records of the data you provide during registration.
Contact Us
For CME Information or credit details contact the American Academy of CME at psicora@academy.org or 609-921-6622
Copyright
©2009 American Academy of CME and CASIVUS Specialty Communications
All rights reserved. None of the contents of this activity may be reproduced in any form without prior written permission from the Academy or CASIVUS.
Hardware/Software Requirements
The simulation requires version 4.x browsers or higher from Microsoft or Netscape or Mozilla FireFox version 1.5.x or higher. Certain activities may require additional software to view multimedia, presentation or printable versions of their content. There are no specific hardware requirements.
|
